primary antibodies cd-163 Search Results


cd163 polyclonal antibody  (Bioss)
91
Bioss cd163 polyclonal antibody
Cd163 Polyclonal Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd163 polyclonal antibody/product/Bioss
Average 91 stars, based on 1 article reviews
cd163 polyclonal antibody - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier
cd163 antibody (ed2) - bsa free  (Bio-Techne corporation)
92
Bio-Techne corporation cd163 antibody (ed2) - bsa free
Cd163 Antibody (Ed2) Bsa Free, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd163 antibody (ed2) - bsa free/product/Bio-Techne corporation
Average 92 stars, based on 1 article reviews
cd163 antibody (ed2) - bsa free - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier
primary monoclonal antibodies targeting cd163 + macrophages  (Bio SB Inc)
90
Bio SB Inc primary monoclonal antibodies targeting cd163 + macrophages
Positive controls used for IHC Analysis
Primary Monoclonal Antibodies Targeting Cd163 + Macrophages, supplied by Bio SB Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary monoclonal antibodies targeting cd163 + macrophages/product/Bio SB Inc
Average 90 stars, based on 1 article reviews
primary monoclonal antibodies targeting cd163 + macrophages - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
primary antibodies against cd163  (MyBiosource Biotechnology)
90
MyBiosource Biotechnology primary antibodies against cd163
(A) Release profile of Dex from microparticles in PBS (n=5). (B) Dex content in the cell culture media (n=3 in blank group and n=6 in treatment groups) following Dex microparticle administration to cells. Media was changed on days 3, 5, and 7. (C-J) Representative images of cells stained for <t>CD163</t> and CCR7 or stained for MerTk and CCR2. (K-N) Image quantification of staining for the surface receptors CD163, CCR7, MerTk, and CCR2 (n=4). Data represent mean ± SEM for all graphs. Statistical analyses were completed by applying one-way ANOVA with Tukey’s post hoc test. *denotes p<0.05 and ** denotes p<0.01. Scale bar = 50 µm.
Primary Antibodies Against Cd163, supplied by MyBiosource Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary antibodies against cd163/product/MyBiosource Biotechnology
Average 90 stars, based on 1 article reviews
primary antibodies against cd163 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
primary cd163 polyclonal antibody  (Wuhan Sanying Biotechnology)
90
Wuhan Sanying Biotechnology primary cd163 polyclonal antibody
(A) Release profile of Dex from microparticles in PBS (n=5). (B) Dex content in the cell culture media (n=3 in blank group and n=6 in treatment groups) following Dex microparticle administration to cells. Media was changed on days 3, 5, and 7. (C-J) Representative images of cells stained for <t>CD163</t> and CCR7 or stained for MerTk and CCR2. (K-N) Image quantification of staining for the surface receptors CD163, CCR7, MerTk, and CCR2 (n=4). Data represent mean ± SEM for all graphs. Statistical analyses were completed by applying one-way ANOVA with Tukey’s post hoc test. *denotes p<0.05 and ** denotes p<0.01. Scale bar = 50 µm.
Primary Cd163 Polyclonal Antibody, supplied by Wuhan Sanying Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary cd163 polyclonal antibody/product/Wuhan Sanying Biotechnology
Average 90 stars, based on 1 article reviews
primary cd163 polyclonal antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Positive controls used for IHC Analysis

Journal: BMC Oral Health

Article Title: Expression of mTOR, CD163, α-SMA, FOXp3 as survival predictors and its significance in patients with oral squamous cell carcinoma

doi: 10.1186/s12903-024-05245-y

Figure Lengend Snippet: Positive controls used for IHC Analysis

Article Snippet: It was followed by incubating the sections with primary monoclonal antibodies targeting FoxP3 + T-cells (prediluted; clone 236 A/E7; Lot: 02122 A; BIOCARE, USA), CD163 + Macrophages (prediluted; clone EP324; Lot:6305FME18; BIOSB, USA), mTOR of tumor cells (prediluted; clone 59.Ser 2448; Lot: MC0509R0622; MEDAYSIS, USA), α-SMA of Cancer associated fibroblasts (prediluted; clone 1A4; Lot:1105092D-3 F; ZETA Corporation, USA) at room temperature overnight.

Techniques: Positive Control

Survival graphs based on high and low expression of markers ( A ) CD163, ( B ) α-SMA, ( C ) mTOR, ( D ) FOXp3

Journal: BMC Oral Health

Article Title: Expression of mTOR, CD163, α-SMA, FOXp3 as survival predictors and its significance in patients with oral squamous cell carcinoma

doi: 10.1186/s12903-024-05245-y

Figure Lengend Snippet: Survival graphs based on high and low expression of markers ( A ) CD163, ( B ) α-SMA, ( C ) mTOR, ( D ) FOXp3

Article Snippet: It was followed by incubating the sections with primary monoclonal antibodies targeting FoxP3 + T-cells (prediluted; clone 236 A/E7; Lot: 02122 A; BIOCARE, USA), CD163 + Macrophages (prediluted; clone EP324; Lot:6305FME18; BIOSB, USA), mTOR of tumor cells (prediluted; clone 59.Ser 2448; Lot: MC0509R0622; MEDAYSIS, USA), α-SMA of Cancer associated fibroblasts (prediluted; clone 1A4; Lot:1105092D-3 F; ZETA Corporation, USA) at room temperature overnight.

Techniques: Expressing

Two marker combination survival analysis (Fig. <xref ref-type= 6 )" width="100%" height="100%">

Journal: BMC Oral Health

Article Title: Expression of mTOR, CD163, α-SMA, FOXp3 as survival predictors and its significance in patients with oral squamous cell carcinoma

doi: 10.1186/s12903-024-05245-y

Figure Lengend Snippet: Two marker combination survival analysis (Fig. 6 )

Article Snippet: It was followed by incubating the sections with primary monoclonal antibodies targeting FoxP3 + T-cells (prediluted; clone 236 A/E7; Lot: 02122 A; BIOCARE, USA), CD163 + Macrophages (prediluted; clone EP324; Lot:6305FME18; BIOSB, USA), mTOR of tumor cells (prediluted; clone 59.Ser 2448; Lot: MC0509R0622; MEDAYSIS, USA), α-SMA of Cancer associated fibroblasts (prediluted; clone 1A4; Lot:1105092D-3 F; ZETA Corporation, USA) at room temperature overnight.

Techniques: Marker, Expressing

Three marker combination survival analysis (Fig. <xref ref-type= 7 )" width="100%" height="100%">

Journal: BMC Oral Health

Article Title: Expression of mTOR, CD163, α-SMA, FOXp3 as survival predictors and its significance in patients with oral squamous cell carcinoma

doi: 10.1186/s12903-024-05245-y

Figure Lengend Snippet: Three marker combination survival analysis (Fig. 7 )

Article Snippet: It was followed by incubating the sections with primary monoclonal antibodies targeting FoxP3 + T-cells (prediluted; clone 236 A/E7; Lot: 02122 A; BIOCARE, USA), CD163 + Macrophages (prediluted; clone EP324; Lot:6305FME18; BIOSB, USA), mTOR of tumor cells (prediluted; clone 59.Ser 2448; Lot: MC0509R0622; MEDAYSIS, USA), α-SMA of Cancer associated fibroblasts (prediluted; clone 1A4; Lot:1105092D-3 F; ZETA Corporation, USA) at room temperature overnight.

Techniques: Marker, Expressing

(A) Release profile of Dex from microparticles in PBS (n=5). (B) Dex content in the cell culture media (n=3 in blank group and n=6 in treatment groups) following Dex microparticle administration to cells. Media was changed on days 3, 5, and 7. (C-J) Representative images of cells stained for CD163 and CCR7 or stained for MerTk and CCR2. (K-N) Image quantification of staining for the surface receptors CD163, CCR7, MerTk, and CCR2 (n=4). Data represent mean ± SEM for all graphs. Statistical analyses were completed by applying one-way ANOVA with Tukey’s post hoc test. *denotes p<0.05 and ** denotes p<0.01. Scale bar = 50 µm.

Journal: bioRxiv

Article Title: Non-Genetic Reprogramming of Monocytes via Microparticle Phagocytosis for Sustained Modulation of Macrophage Phenotype

doi: 10.1101/674598

Figure Lengend Snippet: (A) Release profile of Dex from microparticles in PBS (n=5). (B) Dex content in the cell culture media (n=3 in blank group and n=6 in treatment groups) following Dex microparticle administration to cells. Media was changed on days 3, 5, and 7. (C-J) Representative images of cells stained for CD163 and CCR7 or stained for MerTk and CCR2. (K-N) Image quantification of staining for the surface receptors CD163, CCR7, MerTk, and CCR2 (n=4). Data represent mean ± SEM for all graphs. Statistical analyses were completed by applying one-way ANOVA with Tukey’s post hoc test. *denotes p<0.05 and ** denotes p<0.01. Scale bar = 50 µm.

Article Snippet: Blocked cells were then incubated overnight at 4°C with primary antibodies against BuGR2 (Invitrogen, cat. #MA1-510), CD163 (1:50; MyBioSource, cat. # MBS302638), CCR7 (1:100; OriGene, cat. # TA320232), MerTk (1:200; abcam, cat. # ab216564), and/or CCR2 (1:200; abcam, cat. # ab176390).

Techniques: Cell Culture, Staining